|
Mr. Davidson is a Managing Director of H.I.G. Ventures and focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G., Mr. Davidson served as Vice President for Ventures West, with a focus on venture investing in life sciences companies. He began his career with Eli Lilly Company where he spent a decade in various management roles in the U.S. and Canada including business development, strategic planning, market research, and financial planning. After Lilly, he spent a year as the Vice-President of Corporate Business Development at SYN-X Pharma. Mr. Davidson�s current board seats include Alder Biopharmaceuticals, Gemin X Biotechnologies Inc, HyperBranch Medical Technology, NeurAxon Inc., Novadaq Technologies, Inc. (public June 2005), Oncogenex Technologies Inc. and Tranzyme Pharma. In addition, Mr. Davidson served on the board of Salmedix, Inc. before it was acquired by Cephalon in June 2005. Mr. Davidson has a bachelor of commerce degree from McGill University and an MBA from Harvard Business School. | 